BRAXF (BRAXF) Stock Price & Analysis
BRAXF (BRAXF) rose 0.00% to USD 0 as of June 10, 2026 at 09:12 UTC, according to Nexqual real-time market data.
BRAXF last closed at USD 0; the session ranged USD 0–0 on volume of 480,000 shares. Market capitalization is $28,328, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 09:12 UTC.
Key Statistics (as of June 10, 2026 at 09:12 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 480,000 shares |
| Market Cap | $28,328 |
| Exchange | PNK |
Technical Analysis (BRAXF)
Nexqual's technical model rates BRAXF "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 09:12 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (BRAXF)
Wall Street analysts rate BRAXF "None", per Nexqual as of June 10, 2026 at 09:12 UTC.
| Consensus Rating | None |
|---|
Earnings (BRAXF)
Source: Nexqual, June 10, 2026 at 09:12 UTC.
Financials & Fundamentals (BRAXF)
| Total Revenue | $2.21M |
|---|---|
| Revenue Growth (YoY) | +0.70% |
| Gross Margin | +14.67% |
| Operating Margin | -174.06% |
| Profit Margin | +0.00% |
| ROE | -254.59% |
| Current Ratio | 0.18 |
| Total Cash | $128,344 |
| Total Debt | $636,635 |
| Free Cash Flow | $-970,825 |
Source: Nexqual, June 10, 2026 at 09:12 UTC.
Financial Health Score (BRAXF)
Nexqual rates BRAXF's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 09:12 UTC.
| Growth | Mixed — Revenue +0.7% YoY (latest Q), slow |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $128K cash, no debt |
| Cash Flow | Weak — FCF negative: -$971K, burning cash |
| Efficiency | Critical — ROE -255%, ROA -42.4% |
Ownership (BRAXF)
| Insider Ownership | +5.55% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 283.28M |
| Float | 268.64M |
Source: Nexqual, June 10, 2026 at 09:12 UTC.
Leadership (BRAXF)
BRAXF is led by Peter Rizakos, CFO & Director, per Nexqual as of June 10, 2026 at 09:12 UTC.
| CFO & Director | Peter Rizakos |
|---|
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HAVLF | HAVN LIFE SCIENCES INC. | USD 0 | ▲ 0% |
| MYCOF | MYDECINE INNOVATIONS GROUP INC | USD 2 | ▲ 0% |
| RVVTF | Revive Therapeutics Ltd. | USD 0.03 | ▲ 15.45% |
| LOBEF | LOBE SCIENCES LTD. | USD 0.07 | ▲ 803.75% |
| TRUFF | Red Light Holland Corp. | USD 0.03 | ▲ 0.71% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:12 UTC. This page is informational and not investment advice.